To make an appointment with a Valley cancer specialist,
please call 201-634-5339.
Home > Cancer Services > Research & Clinical Trials > Genito-Urinary Cancer

Genito-Urinary (G.U.) Cancer

Font ++ Click to Print

Trumpet

"Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer"

Study Objectives: To describe patterns of care and disease assessment method, as well as to identify factors influencing physician treatment decisions and settings, referral patterns and CRPC patient characteristics associated with these.

Eligibility: Male patient 18 years or older, willing and able to provide informed consent, confirmed diagnosis of CRPC (defined by a minimum of two rising PSA levels to be measured at least 7 days apart, and serum testosterone level ≤ 1.73 nmol/L (50 ng/dL), or with new evidence of metastatic disease by investigating physician, initiating the first active course of anti-cancer treatment for M0 CRPC or for M1 CRPC (regardless of prior M0 CRPC treatment) such as anti-androgens, androgen synthesis inhibitors, chemotherapy, immunotherapy or radionuclide therapy. Patients may be enrolled within 45 days from the time of treatment initiation, willing and able to complete periodic patient-reported outcome (PRO) questionnaires, with or without assistance, as well as estimated life expectancy of ≥ 6 months.

Principal Investigator: Eli Kirshner, M.D.

Click here for more information on Trumpet


 

NRG-GU003

"A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (Hyport) Versus Conventional Post-Prostatectomy Radiation Therapy (Coport)"

Inclusion:

  • Adenocarcinoma of the prostate, treated with radical prostatectomy (pT2 or pT3), with Gleason < 7
  • No nodal disease or evidence of metastatic disease
  • ECOG 0-1
  • No androgen deprivation therapy prior to surgery for longer than 6 months OR after surgery for greater than 6 weeks prior to enrollment

Treatment:

  • Arm 1: Conventional RT = RT 66.6 Gy in 37 fractions of 1.8 Gy to prostate bed over 7 weeks
  • Arm 2: Hypofractionated RT = RT 62.5 Gy in 25 fractions of 2.5 Gy to prostate bed over 5 weeks

Principal Investigator: Thomas Kole, M.D.

Click here for more information on NRG-GU003



NRG-GU005

Phase III IGRT and SBRT Vs. IGRT and Hypofractionated IMRT For Localized Intermediate Risk Prostate Cancer

Inclusion Criteria:
  • Intermediate risk, previously untreated, localized prostate cancer
  • ECOG 0-1
  • No nodal or metastatic disease
  • No prior/concurrent malignancy within 3 years
  • No use of hormonal therapy

Treatment Randomization:
  • Arm 1: IMRT (28 fractions of 2.5 Gy)
  • Arm 2: SBRT (5 fractions of 7.25 Gy)

Principal Investigator: Thomas Kole, MD

Click here for more information on NRG-GU005 

 

The Valley Hospital Biorepository

For The Valley Hospital (TVH) patients undergoing surgical procedures, we offer the opportunity to participate in TVH Biorepository.  This protocol involves the freezing and storage of extra tissue not used for diagnosis, blood and other bodily fluids that may be used for future research designed to develop or contribute to generalized knowledge in cancer research.


Find a Doctor
 
View all physicians
Contact the Blumenthal Cancer Center

Have a question? Call 201-634-5339 or complete the form below. If you are experiencing a medical emergency, please call your doctor or emergency services provider.

(-
Retype the numbers below:
 Security code
----